Strategic Imperatives for Digital Health Founders: Navigating Beyond AI Hype to Sustainable Enterprise Value
- Nelson Advisors
- 52 minutes ago
- 12 min read
Executive Summary
The digital health ecosystem has transitioned into a mature phase characterised by institutional capital discipline, platform consolidation and rigorous operational scrutiny. Following the capital surge of 2025, during which venture funding in United States digital health startups rebounded to $14.2 billion across 482 completed deals, the market has undergone a structural transformation. Artificial intelligence (AI), which commanded 54% of all digital health venture capital in 2025, has shifted from a novel marketing narrative into an operational baseline. By the first half of 2026, market intelligence platforms ceased tracking "AI-enabled" startups as a distinct investment category because advanced machine learning capability became standard across enterprise health technology architectures.
Despite the volume of capital allocated to AI-centric ventures, a divergence has emerged between early-stage valuation metrics and sustainable enterprise defensibility. A significant cohort of healthtech founders remains preoccupied with proving that their products are "AI first" or "AI enough" to satisfy venture capital mandates. This positioning creates substantial strategic risk. An overemphasis on model parameters and algorithmic positioning often diverts attention from the foundational drivers of enterprise software value: workflow depth, system of record status, native Electronic Health Record (EHR) interoperability, regulatory compliance and reimbursable clinical return on investment (ROI).
The broader healthtech market in 2026 is defined by extreme capital consolidation. While total capital deployment reached $7.4 billion across 244 transactions in the first half of 2026, deal volume remained flat compared to H1 2025, indicating that institutional investors are writing larger checks for a concentrated group of category winners. Nineteen distinct companies secured 45% of all invested capital across twenty mega-deals valued at $100 million or higher in early 2026. Concurrently, health system Chief Information Officers (CIOs) and enterprise buyers are actively rationalising vendor portfolios, aggressively eliminating standalone "point solutions" and technical debt accumulated during pandemic-era software procurement.
Founders who over index on AI messaging risk falling into the "AI-washing" trap. In healthcare,
algorithmically intense point solutions that lack deeply embedded workflow tools and proprietary data loops are highly vulnerable to commoditisation by foundation model providers and core EHR incumbents.
Sustainable competitive advantage in digital health is achieved not through model parameters alone, but by leveraging technology, whether basic automation, deterministic software, or advanced predictive models—to solve structural operational bottlenecks, secure regulatory clearances, establish billing pathways, and capture sticky workflow real estate.
Venture Capital Trajectory and the Mechanics of AI Washing
To contextualise the macroeconomic landscape facing digital health entrepreneurs, it is necessary to examine the progression of venture capital allocation across recent funding cycles. Between 2022 and 2025, the proportion of total digital health capital directed toward AI-focused ventures expanded continuously.
Metric or Financing Period | 2022 | 2023 | 2024 | 2025 | H1 2026 |
Total US Venture Capital Funding ($Bn) | $15.3 | $10.7 | $10.5 | $14.2 | $7.4 |
AI Share of Total Funding (%) | 29% | 33% | 37% | 54% | Baseline Standard |
Average Deal Size ($M) | $18.2 | $15.8 | $20.7 | $29.3 | $30.3 |
Unlabeled Round Share (%) | 12% | 44% | 38% | 35% | 31% |
Mega-Deal Capital Share (% of Total) | 31% | 24% | 28% | 42% | 45% |
The funding dynamic in 2025 demonstrated a clear "AI premium". Digital health startups centering AI in their value proposition commanded a 19% premium on average deal size compared to non-AI peers. Furthermore, participation by mega funds such as Andreessen Horowitz (a16z) and General Catalyst substantially magnified round sizes. For Series A rounds in 2025, lead participation by these institutions elevated average check sizes to $24.1 million, compared to $18.9 million for deals without mega fund backing, a dollar spread that widened to triple digits by Series D.
However, this top-line capital influx masks a structural bifurcation. Despite higher funding totals in 2025, deal volume declined from 509 in 2024 to 482 in 2025, and 35% of all financing transactions were "unlabeled" extension rounds, reflecting persistent difficulty for mid-tier startups seeking valuation step-ups. By 2026, capital consolidated into enterprise grade platforms demonstrating direct EHR integration, proven clinical efficacy and durable recurring revenue models.
The capital concentration of 2024–2025 accelerated widespread "AI-washing", the practice of exaggerating or misrepresenting standard automation, basic rule-based logic, or traditional statistical software as cutting-edge artificial intelligence. Driven by early-stage valuation premiums, founders frequently adopted AI branding to satisfy investor expectations.
This positioning introduces severe operational and commercial vulnerabilities. Overstating algorithmic sophistication creates unrealistic expectations among clinicians, leading to trust erosion when products fail to handle edge cases or produce silent errors in complex care settings. Furthermore, claiming AI capabilities in clinical workflows without appropriate Software as a Medical Device (SaMD) clearances or Clinical Decision Support (CDS) compliance invites regulatory enforcement action from the FDA and FTC.
Commercial buyers perform comprehensive technical diligence. Discovering wrapper architecture or basic third-party API dependencies under the hood often terminates sales cycles with health systems and enterprise payers. The artificial valuation premiums awarded to AI messaging dissipate at Series B and Series C growth stages, where institutional diligence focuses on unit economics, net dollar retention, and gross margin performance.
Tech Stack Consolidation and the Defensibility Matrix
Health system IT leaders are navigating severe operating margin compression, escalating cloud and cybersecurity infrastructure costs, and technical debt accumulated during pandemic-era software deployment. Decentralised purchasing historically led to "shadow IT" proliferation, leaving enterprise buyers with dozens of overlapping point solutions that increased administrative overhead without yielding proportional financial or clinical returns.
Consequently, health system CIOs are executing portfolio consolidation strategies. Rather than licensing standalone "bolt-on" tools, health systems are directing capital toward core systems of record (such as Epic, Cerner and Microsoft) and integrated platform layers that absorb point capabilities. Software applications that require clinicians to exit primary workflows, log into standalone portals, or manually reconcile output data are systematically decommissioned.
The belief that a machine learning model alone constitutes a durable competitive moat is fundamentally flawed in enterprise healthcare. Foundation models are rapidly commoditising and specialised fine-tuned models face ongoing encroachment from foundational AI developers and incumbent health IT vendors. A model that optimises claims processing or clinical triage may offer initial performance gains, but if it lacks native control over the underlying workflow, its defensibility remains fragile. Durable defensibility in digital health is built upon structural software moats, including workflow embededness, system of record status, real-time bidirectional integration infrastructure (such as FHIR and HL7 data pipelines) and proprietary data flywheels generated through daily operational usage.
Structural Feature | AI-Native Point Solution | Embedded Workflow Software Platform |
Primary Value Proposition | Algorithmic task execution and output generation | System-level workflow transformation and outcome ownership |
Customer Interface | Standalone portal, dashboard, or browser extension | Native EHR / ERP embedded interface (FHIR/HL7) |
Defensibility Base | Model weights and temporary performance lead | Deep workflow hooks, data retention, and high switching costs |
Commoditization Risk | High (Vulnerable to LLM updates and vendor add-ons) | Low (High operational barriers to enterprise replacement) |
Gross Margin Structure | Depressed (45%–55%) by API compute and inference costs | High (70%–85%) typical of vertical enterprise software |
Procurement Category | Discretionary IT spend facing active consolidation | Core operational platform aligned with strategic budget |
Understanding technological value creation in healthcare requires evaluating the Jevons Paradox. A common misconception driving the rush toward purely autonomous clinical AI is that technology's primary purpose is to replace clinical labour. However, when technological innovation dramatically lowers the administrative friction and cost of delivering a service, total demand for that service expands rather than contracts.
Administrative burden and access barriers historically rationed care delivery. AI innovations that automate administrative documentation, such as ambient clinical notetakers that reduce documentation times by 70%, do not eliminate clinicians. Instead, by freeing clinical capacity, these tools enable providers to absorb larger patient panels, expand chronic disease management and increase high-margin clinical throughput. Digital health startups that position their technology as an expansion engine for clinical throughput and patient access create far more institutional value than those marketed strictly as labor-replacement cost cutters.
Economic Realities: Compute Costs, Gross Margins and Business Model Durability
A major financial hurdle confronting purely AI-native healthtech startups is gross margin compression. Standard vertical SaaS business models rely on gross margins between 70% and 80%, providing significant operating leverage to fund research, market expansion, and enterprise sales cycles. In contrast, startups heavily reliant on continuous large language model (LLM) API calls, vector database indexing, and cloud inference frequently incur direct compute costs equal to 50% or more of revenue.
This lowers gross margins to 48% or below. Lower gross margins accelerate cash burn, lengthen the runway required to reach cash-flow positivity, and compress valuation multiples during growth-stage fundraising rounds.
To counteract compute cost inflation and achieve financial sustainability, digital health platforms deploy targeted engineering and commercial strategies:
Hybrid Architectural Tiering: Software architectures use deterministic rules and smaller, domain-specific fine tuned models for standard operational tasks, reserving high-cost frontier LLM inference exclusively for complex, non-routine edge cases.
Outcome-Aligned Pricing Structures: Companies move away from pure usage-based or token-indexed pricing models, which penalise founders as usage scales, toward enterprise licensing tied to documented financial metrics, such as denied claim recoveries, administrative hours saved, or fee-for-service reimbursement captured.
Wedge-to-Platform Expansion: Platforms establish an initial, low-friction entry point (such as automated ambient documentation or scheduling triage) and rapidly expand into broader operational software layers to maximise Annual Recurring Revenue (ARR) per Full-Time Equivalent (FTE).
Navigating the Regulatory Landscape: FDA SaMD, PCCP and Governance
Regulatory strategy is a fundamental determinant of product architecture and market access in digital health. Software that influences clinical management must be engineered to align with statutory exemptions or formal medical device review pathways.
Under Section 520(o) of the Federal Food, Drug, and Cosmetic (FD&C) Act (amended by the 21st Century Cures Act), Clinical Decision Support (CDS) software is excluded from the definition of a medical device and thus exempt from premarket FDA review, only if it satisfies four statutory criteria. The software must not acquire, process, or analyse medical images, physiological signals, or signal patterns. It must be intended to display, analyse, or print medical information about a patient. It must support or provide recommendations to a healthcare professional rather than issuing a specific clinical directive. Finally, it must enable the treating clinician to independently review the basis for the recommendations, ensuring the provider does not rely primarily on the software output to make a clinical decision.
If software processes diagnostic signals, generates autonomous treatment directives, or operates as a closed system where the clinician cannot inspect the underlying logic, it crosses into Software as a Medical Device (SaMD). SaMD classification subjects the platform to FDA premarket review pathways: 510(k) Premarket Notification (demonstrating substantial equivalence to a predicate device), De Novo Classification (for novel low-to-moderate risk devices), or Premarket Approval (PMA for high-risk, life-sustaining applications).
Historically, static regulatory paradigms presented challenges for adaptive machine learning systems. Once a device received clearance, updating the underlying algorithm required locking parameters; retraining the model on new data often required a new premarket submission. The FDA addressed this challenge through the Predetermined Change Control Plan (PCCP) framework, finalised in guidance for AI-enabled device software functions. Authorised as part of the initial marketing submission, a PCCP serves as a regulatory agreement that permits manufacturers to iteratively retrain algorithms, adjust decision thresholds, and update model architectures post market without filing new premarket submissions, provided those updates remain within pre-approved boundaries and testing protocols.
A comprehensive PCCP contains three core components: a detailed Description of Modifications outlining bounded, planned changes; a Modification Protocol establishing the exact MLOps protocols, validation methodologies, and data governance standards used to execute changes; and an Impact Assessment evaluating how modifications preserve device safety and effectiveness.
Regulatory Pathway | Applicable Risk Tier | Premarket Review Timeline | Post-Market Governance Controls | Impact on Product Iteration Roadmap |
Exempt Clinical Decision Support (CDS) | Non-Device / Low Risk | Immediate (No premarket review required) | Quality Management System and labeling transparency | Unrestricted logic iteration, provided non-device CDS criteria are maintained. |
510(k) Premarket Notification | Moderate Risk (Class II with Predicate) | ~90 FDA Review Days | Quality System Regulation (21 CFR Part 820 / Part 11) | Static baseline; model retraining requires an authorized PCCP or new submission. |
De Novo Classification | Moderate Risk (Novel Device, No Predicate) | ~150 FDA Review Days | Prospective clinical validation and quality management | Preempts state product liability claims (Dickson v. Dexcom); model updates via PCCP. |
Premarket Approval (PMA) | High Risk (Class III / Life-Sustaining) | ~180+ FDA Review Days | Rigorous Pivotal Clinical Trials and Post-Market Surveillance | Strict change controls; high regulatory barrier creates an enduring competitive moat. |
Modern quality governance was further streamlined by the FDA’s Computer Software Assurance (CSA) guidance. CSA moves away from rigid, script-heavy software validation toward risk-proportionate assurance, allowing healthtech companies to leverage unscripted exploratory testing and vendor documentation. On the legal front, the litigation landscape for cleared SaMD platforms shifted following federal court rulings such as Dickson v. Dexcom, Inc..
Courts established that the Medical Device Amendments (MDA) expressly preempt state product-liability claims against medical software brought to market through the De Novo pathway. This federal preemption offers valuable legal protection for healthtech founders who invest in formal regulatory clearance, establishing a risk barrier that uncleared software products cannot match.
Commercialisation Infrastructure: Reimbursement, EHR Integration and Clinical Outcomes
Sustainable revenue expansion in digital health requires direct alignment with established institutional reimbursement frameworks. Relying on discretionary enterprise SaaS budgets or out-of-pocket consumer payments restricts market reach. Connected care frameworks, specifically Remote Patient Monitoring (RPM) and Remote Therapeutic Monitoring (RTM), provide structured, reimbursable revenue streams established by the Centers for Medicare & Medicaid Services (CMS).
CMS updates to the Medicare Physician Fee Schedule (PFS) establish structured billing tiers for remote care management, creating clear financial incentives for health system adoption.
CPT / HCPCS Billing Code | Operational Service Description | Minimum Data or Engagement Threshold | National Average Reimbursement |
CPT 99453 | Initial device setup and patient onboarding education | Claimed once per episode of care upon device configuration | ~$21.71 |
CPT 99445 | Device supply and daily transmission (Short-Duration RPM) | Minimum 2 days of transmitted data within a 30-day window | ~$52.11 |
CPT 99454 | Device supply and daily transmission (Full Monthly RPM) | Minimum 16 days of transmitted data within a 30-day window | ~$52.11 |
CPT 99470 | Light-touch care management time | 10–19 minutes of clinical care management per calendar month | ~$26.05 |
CPT 99457 | Comprehensive clinical treatment management time | Minimum 20 minutes of interactive clinician communication per month | ~$51.77 |
CPT 99458 | Extended care management time (Add-on code) | Each additional 20 minutes beyond the initial CPT 99457 threshold | ~$41.42 |
CPT 98975–98981 | Remote Therapeutic Monitoring (RTM) | Non-physiologic data (therapy adherence, MSK, respiratory parameters) | Variable by specific code tier |
By engineering software that allows provider organisations to bill these code sets efficiently, while automating background compliance documentation, digital health startups transform their value proposition from an operational expense into a direct revenue driver for healthcare providers.
A persistent commercial barrier in healthtech is the enterprise scaling gap. Industry benchmarks indicate that while 80% of health systems purchase digital health applications, only 25% can demonstrate measurable clinical or financial outcomes, and roughly 75% of digital health initiatives fail to scale beyond the pilot stage. The primary driver of pilot failure is workflow disconnect. Tools that operate as standalone applications struggle to sustain long-term clinical adoption.
To bridge this gap, modern platforms utilise direct workflow integration layers (such as Xealth) and native FHIR-based API connections. Embedding data delivery, clinical risk scoring, and care management directly within primary EHR interfaces (such as Epic Hyperspace or Cerner PowerChart) ensures that user activity and patient outcomes are visible to health system administrators in real time, unlocking full enterprise rollouts.
Strategic Roadmap and Industry Recommendations
The digital health sector has moved past the phase of superficial algorithmic positioning. Founders who spend critical operational cycles worrying if their platforms are "AI-enough" are optimising for the wrong metric. Artificial intelligence is an enabling infrastructure technology; it is not a standalone business model or enterprise moat.
To build durable, high-value enterprise companies, digital health founders should execute against four strategic priorities:
Secure Workflow Real Estate and System-of-Record Status: Prioritise embedding software directly into daily clinical, administrative, or revenue-cycle workflows. Own the core operational interface and build bidirectional EHR integrations that create high switching costs.
Optimise Architecture for Sustainable Unit Economics: Manage inference and compute expenses deliberately. Avoid unnecessary high-cost LLM API calls where deterministic logic or smaller specialised models perform effectively, maintaining gross margins (~70%+) capable of supporting long-term expansion.
Embed Regulatory Strategy into Early Product Engineering: Determine SaMD versus non-device CDS boundaries early in the product lifecycle. Incorporate Predetermined Change Control Plans (PCCPs) into MLOps infrastructure to ensure continuous, post-clearance algorithm iteration without regulatory delays.
Align Commercial Models with Reimbursable Value: Build products that directly capture existing payment pathways, such as Medicare RPM and RTM codes or value-based care incentives. Deliver documented outcomes—such as reduced documentation burden, higher patient throughput, or improved billing capture—that address the core operational priorities of health system CFOs and CIOs.
Enterprise healthcare buyers and institutional investors do not purchase technology for its underlying label; they invest in solutions that solve structural operational, financial, and clinical challenges. Digital health founders who build deeply integrated, regulatory-compliant, and economically sound software platforms will drive the next generation of healthcare innovation.
Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Follow Nelson Advisors LinkedIn Page > https://www.linkedin.com/company/nelson-advisors/
Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
#VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
Comments